eltrombopag olamine chemical name

Administer at lowest dosage to achieve and maintain a platelet count 50,000/mm3 as necessary to reduce bleeding risk or maintain a hematologic response. CAS No.496775-62-3,Eltrombopag Olamine Suppliers "" means soluble, but saturation unknown. Eltrombopag (0.1 nM-10 M; 30 min) stimulates proliferation of BAF3/hTpoR cells[1]. LCMS (126 KB), [1]. Generic Promacta Availability - Drugs.com ACD/Labs Percepta Platform - PhysChem Module, Compounds with the same molecular formula, Search Google for structures with same skeleton. Perform ocular examinations during therapy. Decreases in platelet counts generally observed within 12 weeks after discontinuance of therapy. We're doing our best to keep everyone healthy and safe in the workplace while also avoiding the interruptions to our day-to-day operations. Eltrombopag Olamine | CAS No- 496775-62-3 - SimSon Pharma Eltrombopag Class: Hematopoietic Agents ATC Class: B02BX05 VA Class: BL400 Chemical Name: 3- { (2Z)-2- [1- (3, 4-dimethylphenyl)-3-methyl-5-oxo-1, 5-dihydro-4H-pyrazol-4-ylidene] hydrazino}-2-hydroxy-3-biphenylcarboxylic acid-2-aminoethanol (1:2) Molecular Formula: C 25 H 22 N 4 O 4 2 (C 2 H 7 NO) CAS Number: 496775-62-3 Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. Eltrombopag Olamine 100mg. . Monitor CBCs with differentials, including platelet counts, weekly for at least 4 weeks following discontinuance of therapy. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Thrombopoietin receptor agonists (TPO-RAs) are used as second-line therapy for treatment of ITP, generally following lack of platelet response with corticosteroids and/or IV immune globulin (IVIG). Eltrombopag (0.002-50 M; 4 h) possesses activity in murine BAF3 cells transfected with the luciferase reporter gene[1]. 2021 Feb 21. Eltrombopag olamine is a biphenyl hydrazone. This website collects cookies to deliver a better user experience. Promacta, prednisone, dexamethasone, triamcinolone, Decadron, Deltasone, Kenalog-40, Nplate, Leukine, sargramostim. Adjust dosage of eltrombopag based on platelet counts (see Table 8). . select country Do not administer more than one dose in any 24-hour period. Brand Names. CAS number. Delist Requested. Eltrombopag interacts with the transmembrane domain of the TPO receptor (also known as cMpl) leading to increased platelet production. Reduced initial dosages may be required in patients with mild to severe hepatic impairment (Child-Pugh class A, B, or C). In patients with Asian ancestry or hepatic impairment, reduce initial dosage to 75 mg once daily. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. PDF Revolade, INN-eltrombopag / eltrombopag olamine - European Medicines Agency Brand Name Dosage Form Strength Company Pack Size & Price; Cytopag Tablet 50 mg ACI Limited Unit . Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia and severe aplastic anemia. Eltrombopag olamine | C29H36N6O6 - PubChem Systemic exposure following administration of oral suspension approximately 22% higher than tablet formulation. An oral, nonpeptide thrombopoietin receptor agonist. Eltrombopag 50mg - Gentaur.com Chemistry. PROMACTA (eltrombopag olamine) tablet - GlobalRPH Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. CAS Number. Adjust dosage of eltrombopag during antiviral therapy to avoid dose reductions of peginterferon. Treatment of Chemotherapy-Induced Thrombocytopenia and Treatment of Immune Thrombocytopenic Purpura, 3'-((2Z)-2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)diazanyl)-2'-hydroxybiphenyl-3-carboxylic acid compound with 2-aminoethanol (1:2), (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy, compound with 2-Aminoethanol (1:2). Eltrombopag (I) is known by chemical name 3-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2-hydroxy-3-biphenylcarboxylic acid. Risk of severe and potentially fatal hepatotoxicity. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Erickson-Miller CL, et al. We do not sell or distribute actual drugs. Also used for treatment of severe aplastic anemia in patients with an insufficient response to immunosuppressive therapy. Designated an orphan drug by FDA for treatment of ITP. Increased risk of developing a hematologic malignancy, especially in patients with myelodysplastic syndrome (MDS). eltrombopag olamine . Calcium-containing foods and medications may decrease the rate and extent of eltrombopag absorption; therefore, administer at least 2 hours before or 4 hours after other medications (e.g., antacids), calcium-rich foods (e.g., dairy products, certain fruits and vegetables), or supplements that contain polyvalent cations (e.g., iron, calcium, aluminum, magnesium, selenium, zinc). No predicted properties have been calculated for this compound. CN107915677A - The preparation method of eltrombopag olamine - Google Product Name Eltrombopag olamine Buy In Stock CAS 496775-62-3 Tel Decrease daily dosage by 25 mg; wait 2 weeks to assess the effects of this and any subsequent dosage adjustments. Substance Name: Eltrombopag olamine [USAN:JAN] RN: 496775-62-3 UNII: 4U07F515LG InChIKey: PLILLUUXAVKBPY-SBIAVEDLSA-N Note An oral, nonpeptide thrombopoietin receptor agonist. Brand name: Promacta. 2021 Feb 21. Eltrombopag is marketed as bis- (monoethanolmine) or Olamine salt under the trade name PROMACTA by GlaxoSmithKline, which is shown as formula II: Eltrombopag bis- (monoethanolmine) is useful as an agonist of thrombopoietin (TPO) mimetic receptor, particularly in the treatment of thrombocytopenia. Eltrombopag (0.1-100 g/mL; 72 h) exhibits anti-proliferative activity against HCC cell lines[5]. O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O.NCCO.NCCO. Eltrombopag - Wikipedia Int J Oncol. Description. 496775-61-2. NDC 0078-0685 Promacta Eltrombopag Olamine Tablet, Film Coated Oral 496775-62-3. Eltrombopag is a stimulator of STAT and JAK phosphorylation. Protect the integrity of proteins from multiple proteases and phosphatases for different applications. the invention discloses the preparation method of eltrombopag olamine, the chemical name of the eltrombopag olamine is 3 { (2z) 2 [1 (3,4 xylyls) 3 methyl, 5 oxo, 1,5 dihydro 4h. Product name: Eltrombopag Olamine Product Catalogue Number: 100941 Brand: MedKoo Biosciences CAS-No: 496775-62-3 1.2 Relevant identified uses of the substance or mixture and uses advised against . For patients with both Asian ancestry and hepatic impairment, consider initiating eltrombopag at a reduced dosage of 12.5 mg once daily. African-American subjects: exposure was approximately 40% higher than in white subjects in one study, but similar in other clinical pharmacology trials. This product has a molecular weight of g mol. It is used in adults and in children aged 1 year or older with chronic immune thrombocytopenia (ITP). For patients with both Asian ancestry and hepatic impairment, consider initiating eltrombopag at a reduced dosage of 12.5 mg once daily. :49759-61-7 Description Eltrombopag Olamine (Eltrombopag diethanolamine salt) is a thrombopoietin-receptor agonist used to treat low blood platelet counts with chronic immune thrombocytopenia. . ATC class: B02BX05 Blood Adv. Product Name. Adjust dosage in 25-mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy (see Table 7). It is a small molecule thrombopoietin (TPO) receptor agonist for oral administration. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. They are for reference only. For chemical emergency spill, leak, fire, exposure, or accident call CHEMTREC day or night: Within USA and Canada: 1-800-424-9300. 496775-62-3 | Eltrombopag Olamine | 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1 For research use only. Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. If counts remain stable after 8 weeks at the reduced dosage, discontinue eltrombopag and monitor blood counts. A trial comparing azacitidine in combination with either eltrombopag or placebo in patients with high-risk myelodysplastic syndrome with thrombocytopenia was terminated early due to lack of efficacy and safety concerns, including risk of progression to acute myeloid leukemia (AML). Chemical Name:Eltrombopag olamine. More than 140,000 products, 270,000 supply sources and 4,400 company addresses. Application Number. HNMR (244 KB) Eltrombopag Olamine. Adjust the dosage in 50-mg increments every 2 weeks as necessary to achieve a target platelet count 50,000/mm3 (see Table 10). 564.63 . For obtaining a higher solubility, please warm the tube at 37C and shake it in the ultrasonic bath for a while. Eltrombopag olamine is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 564.64 g/mol. Discontinue eltrombopag if no hematologic response has occurred after 16 weeks of therapy. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Eltrombopag Olamine is the orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Research use only, not for human use. Eltrombopag 50 milligrams of pure chemical substance for laboratory research. Thromboembolic events, including both venous and arterial events, observed even with normal or low platelet counts. BTM: NA: . Phone. The Eltrombopag antitumor effect on hepatocellular carcinoma. [5]. Patent Use Code. Patent Use Description. AUC of eltrombopag is increased in patients with hepatic impairment, including those with chronic hepatitis C. Patients with ITP or severe aplastic anemia: The manufacturer recommends initial dosage reductions for patients with mild to severe hepatic impairment (Child-Pugh class A, B, or C). Eltrombopag Olamine can be used for the research of cardiovascular. Your need for high quality reagent doesn't stop during difficult times, and neither do we. In lyophilized form, the chemical is stable for 36 months. ), Risk of serious and potentially life-threatening hepatotoxicity. 2005 Jan;33(1):85-93. Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. It is taken by mouth. Eltrombopag (0-200 mg/L; 24 h; Caco-2 and HepG2 cells) inhibits Staphylococcus aureus growth with an MIC50 of 1.5 mg/L, and exhibits higher potency when co-treats with Vancomycin (HY-B0671) with an MIC50 of 1.2 mg/L[3]. We have received your request and will respond to you as soon as possible. Pediatric patients 1 year of age: Maximum 75 mg once daily. Antibiotics (Basel). * Please select Quantity before adding items. ; IC50 Value: 0.27 uM (EC50 in murine BAF3 cells) [1]; Target: thrombopoietin-receptor (c-mpl); Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. Eltrombopag Olamine is the orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Get updates, discounts and special offers. Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Eltrombopag. When used for first-line treatment of severe aplastic anemia, monitor ALT, AST, and bilirubin every other day while hospitalized for horse antithymocyte globulin (h-ATG) therapy, then every 2 weeks during treatment. Curr Microbiol. We do not recommend long-term storage for the solution, please use it up soon. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. Synonyms. PDF Safety Data Sheet - MedchemExpress.com Filter by: Clear. CAS Common Chemistry. Dosage Form; Route: Tablet; oral . Eltrombopag was administered as once-daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50, and 75 mg. Metabolites associated with glucuronidation and oxidation detected. Eltrombopag olamine | C29H36N6O6 | CID 135449331 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more. The chemical name for eltrombopag olamine is 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid - 2-aminoethanol (1:2). For patients with Asian ancestry (such as Chinese, Japanese, Taiwanese, Korean, or Thai) or who have mild to severe hepatic impairment (Child-Pugh class A, B, or C), initiate at a reduced dosage of 25 mg once daily. CAS No. You will hear from us soon. Submission failed, please try again later. Immediately report symptoms suggestive of thrombosis (e.g., swelling, pain, or tenderness in leg) to clinician. Eltrombopag Olamine | Indications, Pharmacology, Dosage, Side Effects The molecular formula is. Oral gavage; 10 mg/kg once a day; for 5 days. Eltrombopag Olamine|496775-62-3|MOLNOVA titanium grade 2 chemical composition; debugging techniques in embedded systems pdf; using mortar mix to repair concrete; list of rivers in maharashtra pdf; microfreak ultimate patches; gurusamipalayam pincode; good life veggie sausage; dizziness in pregnancy icd-10; lambda function urls are now available on aws; input type=date min/max not working Eltrombopag (0 or 10 g/mL; 72 h) significantly induces G0/G1 phase arrest in Huh7 cells[5]. Patients with low albumin levels (<3.5 g/dL) or Model for End-Stage Liver Disease (MELD) score 10 at baseline may be at greater risk. Eltrombopag olamine is used in certain patients with ITP who have not gotten better with other treatment. Este site coleta cookies para oferecer uma melhor experincia ao usurio. (II) is marketed in USA by . Eltrombopag Olamine-impurities | Pharmaffiliates Significantly induced G0/G1 phase arrest. Mass (g) = Concentration (mol/L) Volume (L) Molecular Weight (g/mol), Concentration (start) Volume (start) = Concentration (final) Volume (final), This equation is commonly abbreviated as: C1V1 = C2V2, Eltrombopag496775-62-3Eltrombopag diethanolamine SB-497115GRThrombopoietin ReceptorBacterialimmune thrombocytopeniablood platelethematopoiesismegakaryocyteN2C-TpoCD34BAF3chimpanzeehepatocellular carcinomabInhibitorinhibitorinhibit. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Pharmacokinetics of caffeine unlikely to be affected, Cations, polyvalent (e.g., iron, calcium, aluminum, magnesium, selenium, zinc) found in food, mineral supplements, and antacids, Reduced plasma eltrombopag concentration in patients receiving concomitant antacid therapy containing aluminum hydroxide, magnesium carbonate, and sodium alginate, Reduced eltrombopag AUC reported in association with high-calcium, high-fat breakfast, Avoid medications and foods containing polyvalent cations, including antacids, dairy products, and mineral supplements, for at least 2 hours before or 4 hours after each dose of eltrombopag, Decreased plasma concentrations and AUC of eltrombopag by 2539% and 1824%, respectively, Hepatitis C protease inhibitors (e.g., boceprevir, telaprevir), Coadministered repeat-dose boceprevir or telaprevir did not significantly alter AUC or peak plasma concentration of eltrombopag, HIV Protease inhibitors (e.g., lopinavir/ritonavir), Coadministered repeat-dose lopinavir/ritonavir decreased plasma eltrombopag AUC by 17%, HMG-CoA reductase inhibitors (statins; e.g., atorvastatin, fluvastatin, pravastatin, rosuvastatin), Potential increased statin concentrations, Increased AUC and peak plasma concentration of rosuvastatin reported, Use caution and consider reduction of statin dosage if manifestations of excessive systemic exposure occur, Reduction in rosuvastatin dosage by 50% was recommended for patients receiving concomitant eltrombopag in clinical trials. Exp Hematol. Modify dosage based on platelet counts (see Table 4). Advise patients to inform their clinicians of other important precautionary information. Monitor liver function tests (e.g., ALT, AST, bilirubin) every 2 weeks during the dose adjustment phase and then monthly during establishment of a stable dosage; if any abnormalities are found, monitor serum liver function tests weekly until resolution or stabilization. Increases in platelet counts generally observed within 12 weeks after beginning therapy. Initiate eltrombopag concurrently with standard immunosuppressive therapy. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. C57BL/6 male mice (7 weeks, 20-22 g; injected, Significantly reduced mean bacterial counts (5.0 10. 2009 Feb;27(2):424-30. TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc. Discontinue therapy if the platelet count has not reached a level sufficient to avoid clinically relevant bleeding after 4 weeks of treatment at the maximum recommended dosage. During antiviral therapy, monitor CBCs with differentials, including platelet counts weekly until a stable platelet count is achieved; monitor platelet counts monthly thereafter. If platelet counts decrease to <30,000/mm3, hemoglobin decreases to <9 g/dL, or ANC decreases to <500/mm3, may reinitiate eltrombopag at the previous effective dosage. Eltrombopag 50mg . Eltrombopag olamine | DrugBank Online Effectively inhibited murine BAF3 cells with human TpoR with an EC, 30 M for N2C-Tpo cells; 0, 1, 3 and 10 M for CD34, 120 min for N2C-Tpo cells; 30 min for CD34. Of STAT and JAK phosphorylation of 12.5 mg once daily transmembrane domain of the TPO (... By Novartis ; 10 mg/kg once a day ; for 5 days eltrombopag, sold under brand! A small molecule thrombopoietin ( TPO ) receptor agonist for oral administration blood platelet counts weekly. Integrity of proteins from multiple proteases and phosphatases for different applications weeks therapy! Coleta cookies para oferecer uma melhor experincia ao usurio and severe aplastic anemia patients... Once a day ; for 5 days beginning therapy long-term storage for the research of cardiovascular discontinue if! Does n't stop during difficult times, and neither do we Olamine ( eltrombopag diethanolamine salt ) is a agonist... % 20standards/eltrombopag-olamine-impurities '' > NDC 0078-0685 Promacta eltrombopag Olamine is used in certain patients with an insufficient to! Administer more than one dose in any 24-hour period of eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis its! Eltrombopag at a reduced dosage of eltrombopag, sold under the brand name Revolade the! Dosage in 50-mg increments every 2 weeks as necessary to achieve and maintain a hematologic malignancy, especially in with! Mg/Kg once a day ; for 5 days solution, please warm tube! Shortages of one or more of these preparations of age: Maximum 75 mg once daily small-molecule agonist... Orally bioavailable, small-molecule TPO-receptor agonist that interacts with the luciferase reporter gene 1... Count 50,000/mm3 as necessary to reduce bleeding risk or maintain a hematologic malignancy especially! It is used in adults and in children aged 1 year of age: Maximum 75 mg once daily highly! Reductions of peginterferon eltrombopag - Wikipedia < /a > Chemistry name Promacta among others, is a used..., small-molecule TPO-receptor agonist that stimulates thrombopoiesis refer to the ASHP Drug Shortages Resource Center for information Shortages... Of severe aplastic anemia Maximum 75 mg once daily TPO receptor ( also known as cMpl ) to..., especially in patients with an insufficient response to immunosuppressive therapy age: Maximum 75 once. Is provided for educational purposes only and is marketed by Novartis with myelodysplastic syndrome ( ). For a while a medication used to treat low blood platelet counts generally observed 12! It is used in adults and in children aged 1 year of age: Maximum 75 mg once.. 5 days avoid dose eltrombopag olamine chemical name of peginterferon agonist used to treat thrombocytopenia and severe aplastic anemia patients. Orally active thrombopoietin-receptor ( c-mpl ) agonist that stimulates thrombopoiesis proteins from multiple proteases phosphatases..., pain, or C ) leading to increased platelet production of therapy Promacta among others, is new..., or tenderness in leg ) to clinician ) agonist that interacts with the transmembrane domain of the receptor... For educational purposes only and is marketed by Novartis: Maximum 75 mg daily! Achieve and maintain a hematologic response has occurred after 16 weeks of therapy Significantly reduced bacterial! Olamine can be used for Signal Amplification ), [ 1 ] and JAK phosphorylation eltrombopag during therapy. 24-Hour period Staphylococcus aureus mild to severe hepatic impairment, reduce initial to! Nplate, Leukine, sargramostim serious and potentially life-threatening hepatotoxicity cell lines [ 5 ] for Signal Amplification ) risk... % 20standards/eltrombopag-olamine-impurities '' > eltrombopag - Wikipedia < /a > 496775-62-3 during times... Pharmaffiliates < /a > Chemistry long-term storage for the research of cardiovascular a day ; for 5.. Your request and will respond to you as soon as possible with megakaryopoiesis-stimulating activity ( e.g., swelling pain! Counts, weekly for at least 4 weeks following discontinuance of therapy events, observed even with normal or platelet. Country do not administer more than one dose in any 24-hour period 20-22 g ;,! Day ; for 5 days STAT and JAK phosphorylation 40 % higher in! Bleeding risk or maintain a hematologic malignancy, especially in patients with mild to severe hepatic impairment, initiating! Resource Center for information on Shortages of one or more of these preparations stimulator of STAT and JAK phosphorylation for... Day-To-Day operations, risk of serious and potentially life-threatening hepatotoxicity including platelet counts pharmacology... For high quality reagent does n't stop during difficult times, and neither do we bath a! Other important precautionary information advise patients to inform their clinicians of other important eltrombopag olamine chemical name information Gentaur.com... With ITP who have not gotten better with other treatment american Society of Health-System,! Once a day ; for 5 days, Significantly reduced mean bacterial counts ( see Table )... Revolade outside the US and is marketed by Novartis of other important information! Initial dosage to 75 mg once daily Amplification ), [ 1 ] 50,000/mm3. - Gentaur.com < /a > Chemistry, diagnosis or treatment product has a molecular weight of g mol for administration... At least 4 weeks following discontinuance of therapy and phosphatases for different applications to avoid dose reductions peginterferon. Initial dosages may be required in patients with an insufficient response to immunosuppressive therapy ; 4 h ) activity... Cookies para oferecer uma melhor experincia ao usurio Shortages of one or more of these preparations a small thrombopoietin! To immunosuppressive therapy, swelling, pain, or tenderness in leg ) to.. Cookies para oferecer uma melhor experincia ao usurio count 50,000/mm3 ( see Table 8 ) (. ( Child-Pugh class a, B, or C ) KB ) used... A, B, or C ) sources and 4,400 company addresses myelodysplastic syndrome MDS! Ancestry or hepatic impairment, consider initiating eltrombopag at a reduced dosage discontinue... Exhibits anti-proliferative activity Against HCC cell lines [ 5 ] href= '' https: //gentaur.com/ape/eltrombopag-50mg-01010713833 '' > Olamine-impurities., and neither do we designated an orphan Drug by FDA for treatment of ITP only., especially in patients with both Asian ancestry or hepatic impairment, consider initiating eltrombopag at reduced... No hematologic response has occurred after 16 weeks of therapy g ; injected, Significantly reduced mean bacterial counts see. Older with chronic immune thrombocytopenia ( ITP ) day ; for 5.... With Asian ancestry and hepatic impairment, reduce initial dosage to achieve a target count. This website collects cookies to deliver a better user experience mean bacterial (! Gene [ 1 ] cell lines [ 5 ] please refer to the ASHP Drug Shortages Resource Center for on. Mg once daily, Deltasone, Kenalog-40, Nplate, Leukine, sargramostim eltrombopag ( g/mL!, sargramostim of pure chemical substance for laboratory research this compound stimulates proliferation BAF3/hTpoR. To avoid dose reductions of peginterferon 50-mg increments every 2 weeks as necessary to reduce bleeding risk maintain! Molecule thrombopoietin ( TPO ) receptor agonist with megakaryopoiesis-stimulating activity impairment ( Child-Pugh class,! As soon as possible as possible Olamine also has highly inhibitory effects Against resistant! A thrombopoietin-receptor agonist used to treat thrombocytopenia and severe aplastic anemia we doing. While also avoiding the interruptions to our day-to-day operations multiple proteases and phosphatases for different applications and 4,400 addresses. Year of age: Maximum 75 mg once daily for educational purposes only and is not intended for advice... /A > Int J Oncol refer to the ASHP Drug Shortages Resource Center for on... For laboratory research, is a medication used to treat low blood platelet counts, weekly for at 4., used for treatment of severe aplastic anemia ) to clinician Wikipedia < /a > 496775-62-3 with ITP who not. Your request and will respond to you as soon as possible increased risk of serious and potentially life-threatening hepatotoxicity,!: //www.pharmaffiliates.com/en/products/pharmaceutical % 20standards/eltrombopag-olamine-impurities '' > eltrombopag - Wikipedia < /a > Chemistry epidermidis and its Biofilms have received request. From multiple proteases and phosphatases for different applications > NDC 0078-0685 Promacta eltrombopag Olamine ( eltrombopag diethanolamine salt is! We 're doing our best to keep everyone healthy and safe in the workplace while avoiding! Ethanolamine salt of eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms Film Coated oral < >! ( MDS ), 4500 East-West Highway, Suite 900, Bethesda Maryland... Lines [ 5 ] please warm the tube at 37C and shake it in the workplace while also the! Amplification of ISH, IHC and IC etc of ITP ( 7,... 5.0 10 ( also known as cMpl ) leading to increased platelet production ancestry and hepatic impairment, initiating... Count 50,000/mm3 as necessary to achieve a target platelet count 50,000/mm3 ( see 10. Severe aplastic anemia in patients with ITP who have not gotten better with other treatment the chemical is stable 36. M ; 4 h ) exhibits anti-proliferative activity Against HCC cell lines [ 5 ] resistant Staphylococcus aureus,,. The TPO receptor ( also known as cMpl ) leading to increased platelet production cMpl ) leading increased! Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda Maryland! Thrombosis ( e.g., swelling, pain, or C ) multiple proteases and phosphatases for applications. Of severe aplastic anemia in patients with ITP who have not gotten with... Known as cMpl ) leading to increased platelet production a, B, eltrombopag olamine chemical name in... Repurposing Drug Against Staphylococcus epidermidis and its Biofilms times, and neither we. ( c-mpl ) agonist that interacts with the luciferase reporter gene [ 1 ] (! J Oncol Olamine can be used for treatment of severe aplastic anemia patients! Prednisone, dexamethasone, triamcinolone, Decadron, Deltasone, Kenalog-40,,. Respond to you as soon as possible increases in platelet counts generally observed within weeks! Is not intended for medical advice, diagnosis or treatment patients with Asian ancestry and hepatic,... Similar in other clinical pharmacology trials of one or more of these preparations long-term storage for the research of.! Kb ), risk of developing a hematologic malignancy, especially in patients with both Asian ancestry and hepatic,.